Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.

Find People
Find Everything
About This Site
Edit My Profile
Export RDF
Login to Profiles

Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.

Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.

View in: PubMed

subject areas

Cost-Benefit Analysis
Diabetes Mellitus, Type 2
Health Care Costs
Humans
Liver Cirrhosis
Markov Chains
Models, Economic
Predictive Value of Tests
Quality of Life
Quality-Adjusted Life Years
Reproducibility of Results
Risk Factors
Risk Reduction Behavior
Treatment Outcome
United States

authors with profiles

Mary Rinella